Verastem Oncology (NASDAQ: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced its 2025 priorities and upcoming ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

NEEDHAM, MA - Verastem, Inc. (NASDAQ:VSTM), a $247.5 million market cap biopharmaceutical company focused on developing and ...

Verastem, Inc. (NASDAQ: VSTM) recently disclosed in an 8-K filing with the Securities and Exchange Commission that on January 13, 2025, the company entered into a Note Purchase Agreement with RGCM SA ...

Hinge Bio raises $30M Series A for lupus drug; Keros halts trial dosing; Inflammasome reports eye treatment data; J&J files bladder cancer therapy; Verastem licenses KRAS drug ...

Boston, USA-based Verastem Oncology today announced the appointment of Matthew Ros as chief operating officer (COO). In his ...

Verastem Inc. (VSTM), doing business as Verastem Oncology, Wednesday announced the appointment of Matthew Ros as chief operating ...

Oncology announced the appointment of Matthew E. Ros as chief operating officer. In his role, Mr. Ros will report to Dan ...

BOSTON, January 15, 2025--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to ...

Verastem Oncology (Nasdaq: VSTM) has exercised its option to license certain rights to the cancer candidate VS-7375 from ...

Almost finished… We need to confirm your email address. To complete the subscription process, please click the link in the email we just sent you. Daily news – Get the most important news from ...

Jan. 15, 2025 — Scientists have come up with a drug that is a potential candidate for tackling memory deficits in the early stages of the disease in rodents. ... New Innovative Local Treatment ...